• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPRX alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 3)*
     

     
    Kiora Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.01 per share
     
     
    (Title of Class of Securities)
     

     
    49721T507
     
     
    (CUSIP Number)
     

     
    September 30, 2024
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    109,160
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    109,160
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    109,160(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.5%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 1,206 warrants to purchase common stock (“February Warrants”), (ii) 6,944 warrants to purchase common stock (“July Warrants”), and (iii) 101,010 warrants to purchase common stock (“June Warrants,” together with the February Warrants and the July Warrants, the “Warrants”).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    109,160
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    109,160
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    109,160(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.5%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 1,206 February Warrants, (ii) 6,944 July Warrants, and (iii) 101,010 June Warrants.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    109,160
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    109,160
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    109,160(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.5%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of (i) 1,206 February Warrants, (ii) 6,944 July Warrants, and (iii) 101,010 June Warrants.



    Item 1.
    (a)
    Name of Issuer
     
     
    Kiora Pharmaceuticals, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    332 Encinitas Blvd.
    Suite 102
    Encinitas, CA 92024

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •    Lind Global Fund II LP, a Delaware limited partnership;
    •    Lind Global Partners II LLC, a Delaware limited liability company; and
    •    Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.01 per share
    (e)
    CUSIP Number
     
     
    49721T507
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1                  Joint Filing Agreement by and among the Reporting Persons

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14, 2024
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $KPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KPRX

    DatePrice TargetRatingAnalyst
    1/19/2022$2.50Buy
    Maxim Group
    More analyst ratings

    $KPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

      SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 7:17:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:45:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:32:42 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/12/24 6:32:55 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shapiro Aron bought $10,800 worth of shares (3,000 units at $3.60) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/11/24 7:02:13 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walters-Hoffert Lisa bought $4,825 worth of shares (1,250 units at $3.86) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      8/20/24 1:00:12 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    SEC Filings

    See more
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/4/25 2:34:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/3/25 7:00:35 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      5/9/25 7:02:08 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Kiora Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50

      1/19/22 8:19:46 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Leadership Updates

    Live Leadership Updates

    See more

    $KPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

      Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

      4/21/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

      Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and

      9/13/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

      Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e

      2/1/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Tosca Melissa was granted 7,772 shares, increasing direct ownership by 57% to 21,371 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:29:26 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Daniels Eric Joseph was granted 7,772 shares, increasing direct ownership by 42% to 26,375 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:59 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strem Brian M. was granted 15,941 shares, increasing direct ownership by 53% to 46,103 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

      Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w

      6/15/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

      Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones," said Brian M. Strem, Ph.D., president and CEO of Kiora. "Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonst

      5/9/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

      Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia and a co-investigator in the study.Patients with Retinitis Pigmentosa (RP)

      5/1/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care